aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Affinia Therapeutics, founded with the mission to transform the lives of those affected by devastating diseases, focuses on developing innovative gene therapies. The company's core vision is to expand the possibilities of adeno-associated virus (AAV) gene therapy, particularly for muscle and central nervous system (CNS) diseases with significant unmet needs. Leveraging its proprietary ART (Affinia Rationally-designed Therapies) platform, Affinia Therapeutics combines synthetic and systems biology with high-throughput screening to design novel vectors and develop transformative medicines.
Notable figures associated with Affinia Therapeutics include experts in biotechnology and gene therapy, although specific names are not provided. The company has garnered attention from significant investors in the biotech sector, contributing to its rapid growth and development. Key achievements include advancements in AAV vector design and preclinical success in targeting muscle and CNS diseases. Affinia Therapeutics' impact lies in its potential to provide groundbreaking treatments for conditions that currently lack effective therapies, thereby making a lasting positive impact on patients' lives.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Gene Therapies
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Platform, Software
Revenue Type(s)
Enterprise, Small Business
Customer Type(s)
Global
When was Affinia Therapeutics founded?
Affinia Therapeutics was founded in 2019.
Where is Affinia Therapeutics’s headquarters located?
Affinia Therapeutics’s headquarters is located in Waltham, MA, US.
When was Affinia Therapeutics’s last funding round?
Affinia Therapeutics’s most recent funding round was for $110M (USD) in May 2021.
How many employees does Affinia Therapeutics have?
Affinia Therapeutics has 75 employees as of Feb 5, 2024.
How much has Affinia Therapeutics raised to-date?
As of July 05, 2023, Affinia Therapeutics has raised a total of $170M (USD) since May 3, 2021.
Add Comparison
Total Raised to Date
$170M
USD
Last Update May 3, 2021
Last Deal Details
$110M
USD
May 3, 2021
Series B
Total Employees Over Time
75
As of Feb 2024
Affinia Therapeutics Address
100 Beaver Street
Waltham,
Massachusetts
02453
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts